Journal
STEM CELL RESEARCH
Volume 5, Issue 1, Pages 4-22Publisher
ELSEVIER
DOI: 10.1016/j.scr.2010.02.002
Keywords
-
Funding
- Stem Cells for Safer Medicine (www.SC4SM.org) consortium
- EPSRC
- BBSRC
- Wellcome Trust
- Manchester NIHR Biomedical Research Centre
- BBSRC [BB/E010040/1, BB/D014670/2] Funding Source: UKRI
- EPSRC [DT/E005039/2, DT/E005039/1] Funding Source: UKRI
- MRC [MC_G1000732] Funding Source: UKRI
- Biotechnology and Biological Sciences Research Council [BB/E010040/1, BB/D014670/2] Funding Source: researchfish
- Engineering and Physical Sciences Research Council [DT/E005039/2, DT/E005039/1] Funding Source: researchfish
- Medical Research Council [MC_G1000732] Funding Source: researchfish
Ask authors/readers for more resources
Hepatotoxicity is an enormous and increasing problem for the pharmaceutical industry. Early detection of problems during the drug discovery pathway is advantageous to minimize costs and improve patient safety. However, current cellular models are sub-optimal. This review addresses the potential use of pluripotent stem cells in the generation of hepatic cell lineages. It begins by highlighting the scale of the problem faced by the pharmaceutical industry, the precise nature of drug-induced liver injury and where in the drug discovery pathway the need for additional cell models arises. Current research is discussed, mainly for generating hepatocyte-like cells rather than other liver cell-types. In addition, an effort is made to identify where some of the major barriers remain in translating what is currently hypothesis-driven laboratory research into meaningful platform technologies for the pharmaceutical industry. (C) 2010 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available